69. A composition comprising at least six prepared human immunodeficiency virus-1 (HIV-1) epitopes each consisting of an amino acid sequence selected from the group consisting of:

VLAEAMSQV, MTNNPPIPV, KLVGKLNWA,
LVGPTPVNI, KMIGGIGGFI, TLNFPISPI,
KLTPLCVTL, LLQLTVWGI, SLLNATDIAV,
LTFGWCFKL, AIIRILQQL, RILQQLLFI,
KVYLAWVPAHK, MTKILEPFR, AIFQSSMTK,
VTIKIGGQLK, TTLFCASDAK, VTVYYGVPVWK,
QMVHQAISPR, PYNTPVFAI, YWQATWIPEW
IWGCSGKLI, VWKEATTTLF, IYETYGDTW,
PYNEWTLEL, KIQNFRVYYR, IPYNPQSQGVV,
EVNIVTDSQY, FRDYVDRFY, VIYQYMDDLY,
VTVLDVGDAY, IYQEPFKNL, TYQIYQEPF,
QMAVFIHNFK QKQITKIQNFRVYYR, IKQFINMWQEVGKAMY,
WAGIKQEFGIPYNPQ, GAVVIQDNSDIKVVP WEFVNTPPLVKLWYQ,
KVYLAWVPAHKGIGG, GEIYKRWIILGLNKI, EKVYLAWVPAHKGIG,
QHLLQLTVWGIKQLQ, QGQMVHQAISPRTLN, SPAIFQSSMTKILEP,
FRKYTAFTIPSINNE, HSNWRAMASDFNLPP, KTAVQMAVFIHNFKR,
YRKILRQRKIDRLID, EVNIVTDSQYALGII, and AETFYVDGAANRETK.

70. The composition of claim 69, further comprising at least one epitope selected from the group consisting of ILKEPVHGV, QVPLRPMTYK, VMIVWQVDR, FPISPIETV, CPKVSFEPI, FPVRPQVPL, RYLKDQQLL, KRWIILGLNKIVRMY, MASDFNLPPV, KAACWWAGI, RAMASDFNL, YPLASLRSLF, HPVHAGPIA, IPIHYCAPA, and VPLQLPPL.--

REMARKS

With entry of the present amendment, claims 1-39 are canceled and claims 40-70 are pending in the application.

Claims 40, 41, 44, 54, 55, 58, 69, and 70 recite a prepared epitope consisting of an amino acid sequence selected from the group set out in the claims. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, in Tables XXXVIII and XXXIX at pages 427 and 428.

Claims 42, 43, 54, 63, 64, 65, and 66 recite a composition further comprising two (claim 42 and 54), three (claims 43 and 63), four (claim 64), five (claim 65), or six (claim 66) epitopes. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, on page 30, lines 28-31, page 43, lines 21-22, and page 46, lines 2-7.

Claims 45, 46, 59, and 60 recite a composition that further comprises an HTL epitope (claims 45 and 59) and an HTL epitope that is a pan DR binding molecule (claims 46 and 60). This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 27, lines 24-25 and page 51, line 12 through page 52, line 17.

Claims 50 and 51 recite an antigen presenting cell and an antigen-presenting cell that is a dendritic cell, respectively. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 45, lines 5-21.

Claims 47 and 61 recite a peptide on or within a liposome. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, 56, line 29 through page 57, line 17.

Claims 48 and 62 recite a peptide joined to a lipid. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, page 52, lines 25-30.

Claim 54 recites a peptide that is 250 amino acids or less in length. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 80, lines 29-32.

Claims 52 and 67, and 53 and 68, recite a composition further comprising a pharmaceutical excipient and an epitope in a unit dose form, respectively. This amendment adds no new matter. Support for the amendment can be found throughout the specification,

e.g., page 56 lines 4-18, page 57, line 18 through page 58, line 2, page 56, lines 23-28, and page 58, lines 5-12.

Claim 56 recites at least two epitopes linked via a spacer. This amendment adds no new matter. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, page 51, lines 17-25.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JML
SF 1077654 v1